

Thushan I De Silva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5505793/publications.pdf>

Version: 2024-02-01

79
papers

7,697
citations

257357

24
h-index

102432

66
g-index

107
all docs

107
docs citations

107
times ranked

16955
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterising within-hospital SARS-CoV-2 transmission events using epidemiological and viral genomic data across two pandemic waves. <i>Nature Communications</i> , 2022, 13, 671.	5.8	33
2	Divergent trajectories of antiviral memory after SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, 1251.	5.8	20
3	Tracking SARS-CoV-2 Mutations & Variants Through the COG-UK-Mutation Explorer. <i>Virus Evolution</i> , 2022, 8, veac023.	2.2	19
4	Protocol for the COG-UK hospital-onset COVID-19 infection (HOCl) multicentre interventional clinical study: evaluating the efficacy of rapid genome sequencing of SARS-CoV-2 in limiting the spread of COVID-19 in UK NHS hospitals. <i>BMJ Open</i> , 2022, 12, e052514.	0.8	12
5	Procalcitonin Is Not a Reliable Biomarker of Bacterial Coinfection in People With Coronavirus Disease 2019 Undergoing Microbiological Investigation at the Time of Hospital Admission. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac179.	0.4	10
6	Altered subgenomic RNA abundance provides unique insight into SARS-CoV-2 B.1.1.7/Alpha variant infections. <i>Communications Biology</i> , 2022, 5, .	2.0	12
7	Improved sensitivity using a dual target, E and RdRp assay for the diagnosis of SARS-CoV-2 infection: Experience at a large NHS Foundation Trust in the UK. <i>Journal of Infection</i> , 2021, 82, 159-198.	1.7	29
8	D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. <i>Cell Host and Microbe</i> , 2021, 29, 23-31.e4.	5.1	308
9	Cryptic prophages within a <i>Streptococcus pyogenes</i> genotype emm4 lineage. <i>Microbial Genomics</i> , 2021, 7, .	1.0	7
10	Subgenomic RNA identification in SARS-CoV-2 genomic sequencing data. <i>Genome Research</i> , 2021, 31, 645-658.	2.4	48
11	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. <i>Nature Communications</i> , 2021, 12, 2055.	5.8	102
12	Rapid feedback on hospital onset SARS-CoV-2 infections combining epidemiological and sequencing data. <i>ELife</i> , 2021, 10, .	2.8	26
13	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2021, 12, 5061.	5.8	150
14	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. <i>Lancet Microbe</i> , The, 2021, 2, e354-e365.	3.4	216
15	Long-term survivors following autologous haematopoietic stem cell transplantation have significant defects in their humoral immunity against vaccine preventable diseases, years on from transplant. <i>Vaccine</i> , 2021, 39, 4778-4783.	1.7	6
16	Genomic and Epidemiological Analysis of SARS-CoV-2 Viruses in Sri Lanka. <i>Frontiers in Microbiology</i> , 2021, 12, 722838.	1.5	9
17	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. <i>Cell</i> , 2021, 184, 5699-5714.e11.	13.5	262
18	The Alpha variant was not associated with excess nosocomial SARS-CoV-2 infection in a multi-centre UK hospital study. <i>Journal of Infection</i> , 2021, 83, 693-700.	1.7	11

#	ARTICLE	IF	CITATIONS
19	The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. <i>IScience</i> , 2021, 24, 103353.	1.9	57
20	Generation of a Novel SARS-CoV-2 Sub-genomic RNA Due to the R203K/G204R Variant in Nucleocapsid: Homologous Recombination has Potential to Change SARS-CoV-2 at Both Protein and RNA Level. <i>Pathogens and Immunity</i> , 2021, 6, 27-49.	1.4	10
21	Generation of a Novel SARS-CoV-2 Sub-genomic RNA Due to the R203K/G204R Variant in Nucleocapsid: Homologous Recombination has Potential to Change SARS-CoV-2 at Both Protein and RNA Level. <i>Pathogens and Immunity</i> , 2021, 6, 27-49.	1.4	46
22	Complexities in Predicting the Immunogenicity of Live Attenuated Influenza Vaccines. <i>Clinical Infectious Diseases</i> , 2020, 70, 2235-2236.	2.9	2
23	Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. <i>Nature Immunology</i> , 2020, 21, 1336-1345.	7.0	1,066
24	Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. <i>Cell</i> , 2020, 182, 812-827.e19.	13.5	3,551
25	Asymptomatic SARS-CoV-2 infection: the tip or the iceberg?. <i>Thorax</i> , 2020, 75, 621-622.	2.7	21
26	Roll-out of SARS-CoV-2 testing for healthcare workers at a large NHS Foundation Trust in the United Kingdom, March 2020. <i>Eurosurveillance</i> , 2020, 25, .	3.9	143
27	A comparison of viral microneutralization and haemagglutination inhibition assays as measures of seasonal inactivated influenza vaccine immunogenicity in the first year after reduced intensity conditioning, lymphocyte depleted allogeneic haematopoietic stem cell transplant. <i>Vaccine</i> , 2019, 37, 452-457.	1.7	2
28	Effect of a Russian-backbone live-attenuated influenza vaccine with an updated pandemic H1N1 strain on shedding and immunogenicity among children in The Gambia: an open-label, observational, phase 4 study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 665-676.	5.2	34
29	Genomic and Epidemiological Evidence of a Dominant Pantone-Valentine Leucocidin-Positive Methicillin Resistant <i>Staphylococcus aureus</i> Lineage in Sri Lanka and Presence Among Isolates From the United Kingdom and Australia. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 123.	1.8	7
30	The efficacy, effectiveness, and immunogenicity of influenza vaccines in Africa: a systematic review. <i>Lancet Infectious Diseases</i> , 2019, 19, e110-e119.	4.6	17
31	Low-Bias RNA Sequencing of the HIV-2 Genome from Blood Plasma. <i>Journal of Virology</i> , 2019, 93, .	1.5	11
32	HLA-associated polymorphisms in the HIV-2 capsid highlight key differences between HIV-1 and HIV-2 immune adaptation. <i>Aids</i> , 2018, 32, 709-714.	1.0	6
33	Acceptability of intranasal live attenuated influenza vaccine, influenza knowledge and vaccine intent in The Gambia. <i>Vaccine</i> , 2018, 36, 1772-1780.	1.7	10
34	Sociodemographic and psychological determinants of influenza vaccine intention among recipients of autologous and allogeneic haematopoietic stem cell transplant: a cross-sectional survey of UK transplant recipients using a modified health belief model. <i>BMJ Open</i> , 2018, 8, e021222.	0.8	8
35	Potential impact of influenza vaccine roll-out on antibiotic use in Africa. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2197-2200.	1.3	13
36	Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes. <i>Bone Marrow Transplantation</i> , 2017, 52, 775-777.	1.3	16

#	ARTICLE	IF	CITATIONS
37	Value of immunogenicity studies of influenza vaccine in resource-limited settings. <i>The Lancet Global Health</i> , 2017, 5, e274.	2.9	0
38	Comparison of mucosal lining fluid sampling methods and influenza-specific IgA detection assays for use in human studies of influenza immunity. <i>Journal of Immunological Methods</i> , 2017, 449, 1-6.	0.6	25
39	Bilateral Ocular Myositis Associated with Whipple's Disease. <i>Ocular Oncology and Pathology</i> , 2017, 3, 17-21.	0.5	10
40	Viral Evolution and Cytotoxic T Cell Restricted Selection in Acute Infant HIV-1 Infection. <i>Scientific Reports</i> , 2016, 6, 29536.	1.6	13
41	Predicting the extinction of HIV-2 in rural Guinea-Bissau. <i>Aids</i> , 2015, 29, 2479-2486.	1.0	14
42	A novel <i>KIR3DL1*0150103</i> subtype identified in West Africa. <i>Tissue Antigens</i> , 2015, 86, 70-71.	1.0	0
43	<i>KIR3DL1*0040102</i> – a novel three-domain <i>KIR</i> subtype isolated from donors of African descent. <i>Tissue Antigens</i> , 2015, 86, 220-221.	1.0	0
44	<i>KIR3DL1*0250103</i> : a novel three-domain <i>KIR</i> allele isolated in West African samples. <i>Tissue Antigens</i> , 2015, 86, 150-151.	1.0	0
45	Full-length sequence of <i>KIR3DL1*0310102</i> detected in DNA samples from West Africa. <i>Tissue Antigens</i> , 2015, 86, 312-313.	1.0	0
46	Cutaneous leishmaniasis acquired during a brief visit to Cyprus. <i>Journal of Infection</i> , 2015, 70, 314-316.	1.7	1
47	Early Virological and Immunological Events in Asymptomatic Epstein-Barr Virus Infection in African Children. <i>PLoS Pathogens</i> , 2015, 11, e1004746.	2.1	64
48	<i>KIR3DL1*0250102</i> : a novel three-domain <i>KIR</i> subtype identified in West Africa. <i>Tissue Antigens</i> , 2015, 85, 151-152.	1.0	0
49	Identification of a novel three-domain <i>KIR</i> allele: <i>KIR3DL1*087</i> using high-resolution molecular techniques. <i>Tissue Antigens</i> , 2015, 85, 153-154.	1.0	0
50	Full-length sequence of <i>KIR3DL1*01501</i> allele found in Sub-Saharan Africa by long-range sequencing. <i>Tissue Antigens</i> , 2014, 83, 126-127.	1.0	3
51	A novel <i>KIR3DL1*0200102</i> allele isolated from a West African donor by sequence-based typing. <i>Tissue Antigens</i> , 2014, 83, 305-306.	1.0	1
52	A new variant of killer cell immunoglobulin-like receptor <i>KIR3DL1*03101</i> isolated using sequence-based techniques. <i>Tissue Antigens</i> , 2014, 84, 521-522.	1.0	0
53	Genomic full length sequence of a novel killer cell immunoglobulin-like receptor, <i>KIR3DL1*0010103</i> identified by sequencing. <i>Tissue Antigens</i> , 2014, 84, 520-521.	1.0	0
54	Successful use of Fendrix in HIV-infected non-responders to standard hepatitis B vaccines. <i>Journal of Infection</i> , 2014, 68, 397-399.	1.7	17

#	ARTICLE	IF	CITATIONS
55	Full-length <i>KIR3DL1*022</i> detected in an African donor. <i>Tissue Antigens</i> , 2014, 84, 427-429.	1.0	0
56	Boosting of HIV-1 Neutralizing Antibody Responses by a Distally Related Retroviral Envelope Protein. <i>Journal of Immunology</i> , 2014, 192, 5802-5812.	0.4	4
57	Isolation of full-length genomic sequences of the <i>KIR3DL1*0040103</i> allele from African donors using sequence-based techniques. <i>Tissue Antigens</i> , 2014, 84, 594-595.	1.0	0
58	Complete genomic sequence of <i>KIR3DL1*0150102</i> . <i>Tissue Antigens</i> , 2014, 84, 595-596.	1.0	0
59	Description of a novel <i>KIR3DL1*0150211</i> allele isolated using molecular techniques. <i>Tissue Antigens</i> , 2014, 84, 596-597.	1.0	0
60	Correlates of T-cell-mediated viral control and phenotype of CD8+ T cells in HIV-2, a naturally contained human retroviral infection. <i>Blood</i> , 2013, 121, 4330-4339.	0.6	56
61	Population dynamics of HIV-2 in rural West Africa. <i>Aids</i> , 2013, 27, 125-134.	1.0	32
62	Molecular Epidemiology of Endemic Human T-Lymphotropic Virus Type 1 in a Rural Community in Guinea-Bissau. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1690.	1.3	22
63	Monocytes Regulate the Mechanism of T-cell Death by Inducing Fas-Mediated Apoptosis during Bacterial Infection. <i>PLoS Pathogens</i> , 2012, 8, e1002814.	2.1	25
64	Potent Autologous and Heterologous Neutralizing Antibody Responses Occur in HIV-2 Infection across a Broad Range of Infection Outcomes. <i>Journal of Virology</i> , 2012, 86, 930-946.	1.5	51
65	T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells. <i>Blood</i> , 2012, 119, 2083-2092.	0.6	29
66	Maternal Proviral Load and Vertical Transmission of Human T Cell Lymphotropic Virus Type 1 in Guinea-Bissau. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 584-590.	0.5	12
67	Immune Reconstitution Inflammatory Syndrome and the Influence of T Regulatory Cells: A Cohort Study in the Gambia. <i>PLoS ONE</i> , 2012, 7, e39213.	1.1	12
68	Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings. <i>AIDS Research and Treatment</i> , 2011, 2011, 1-11.	0.3	39
69	HTLV-1 and HIV-2 Infection Are Associated with Increased Mortality in a Rural West African Community. <i>PLoS ONE</i> , 2011, 6, e29026.	1.1	35
70	Mortality and immunovirological outcomes on antiretroviral therapy in HIV-1 and HIV-2-infected individuals in the Gambia. <i>Aids</i> , 2011, 25, 2167-2175.	1.0	38
71	HIV-1 subtype distribution in the Gambia and the significant presence of CRF49_cpx, a novel circulating recombinant form. <i>Retrovirology</i> , 2010, 7, 82.	0.9	11
72	HIV-2 capsids distinguish high and low virus load patients in a West African community cohort. <i>Vaccine</i> , 2010, 28, B60-B67.	1.7	43

#	ARTICLE	IF	CITATIONS
73	Presence of a Multidrugâ€Resistance Mutation in an HIVâ€2 Variant Infecting a Treatmentâ€Naive Individual in Caio, Guinea Bissau. <i>Clinical Infectious Diseases</i> , 2009, 48, 1790-1793.	2.9	11
74	HIV-2: the forgotten AIDS virus. <i>Trends in Microbiology</i> , 2008, 16, 588-595.	3.5	165
75	Resisting Immune Exhaustion in HIV-1 Infection. <i>PLoS Medicine</i> , 2008, 5, e103.	3.9	5
76	HIV-1 Infection and the Kidney: An Evolving Challenge in HIV Medicine. <i>Mayo Clinic Proceedings</i> , 2007, 82, 1103-1116.	1.4	53
77	Significance of Low Positive Scores Obtained with a Method Other than Acceleration in the BDProbeTec-Strand Displacement Amplification Test for Detection of <i>Neisseria gonorrhoeae</i> . <i>Journal of Clinical Microbiology</i> , 2006, 44, 4628-4629.	1.8	4
78	Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust. <i>Wellcome Open Research</i> , 0, 6, 220.	0.9	6
79	Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust. <i>Wellcome Open Research</i> , 0, 6, 220.	0.9	4